Phenomix Corporation Announces Positive Results from a Phase 3 Study of Dutogliptin in Type 2 Diabetes Mellitus
SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix’ internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.